Opinion|Videos|December 1, 2025
NIRVANA Study Findings on Early Onset of VMS and Sleep Relief
Author(s)Fiona C. Baker, PhD
Fiona C. Baker, PhD, reviews NIRVANA’s findings showing early onset of relief for both VMS and sleep disturbances, supported by patient-reported improvements in sleep quality, duration, and nighttime awakenings.
Advertisement
Episodes in this series
The NIRVANA study demonstrated early and meaningful improvements in both vasomotor symptoms and sleep, with some benefits reported as soon as the first week of treatment. Objective data showed reductions in wakefulness after sleep onset and fewer nighttime awakenings, reinforcing the subjective improvements reported by participants. Together, these findings validate that symptom relief is both rapid and measurable across multiple modalities.
Advertisement
Related to this article
ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.
Joint guidance from the AHA, AAP, ACOG, and SMFM organizes cardiovascular prevention for girls and women around 4 female life stages.
Get caught up with Contemporary OB/GYN's latest coverage from The Menopause Society Annual Meeting in San Diego, California.
Hormone therapy was associated with more frequent, longer migraines in postmenopausal women, but not with greater severity or analgesic use.
NK receptor antagonists significantly improved sleep disturbance in menopausal women at 4, 12, and 24 weeks in a meta-analysis of RCTs.
Perimenopausal women who were more physically active had significantly lower symptom burden across all domains, a study of 1808 Flo app users found.
Perimenopausal women over-reported total sleep time by a mean of 35.3 minutes and under-reported wake time compared with Fitbit data.
Elinzanetant cut moderate-to-severe VMS frequency by ≥50% in 66.9% of US participants compared with 40.5% on placebo.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
ACOG advises against GLP-1 receptor agonists during pregnancy
2
Safety Monitoring and Dosing for NK3 Antagonists in Menopause VMS
3
Susan Reed, MD, on the future of menopause research and funding
4
Matthew Nudy, MD, on estrogen and the cardiovascular system
5